News

OCEAN and HORIZON Trials: More Benefit Than Risk With Melflufen Plus Dexamethasone in Myeloma?

Mount Sinai Receives $7 Million Grant for High-Risk Multiple Myeloma Research

Is ASCT Feasible in Selected Older Patients With Multiple Myeloma?

ASCO Quality 2023: When Are Older Black and White Patients With Myeloma Initiating Therapy?

Brazilian Experience With COVID-19 Infections in Patients With Myeloma

ASCO Quality 2023: Electronic Platform for Gathering Social Determinants of Health in Myeloma

ASCO Quality 2023: Caring for Patients With Active Myeloma at Home

ASCO Quality 2023: Antiresorptive Therapy and Myeloma-Related Skeletal Disease

ASCO Quality 2023: Surveyed Patients Balance Risks and Benefits of Myeloma Treatment

Can Health of the Immune System Help Predict the Duration of Remission in Myeloma?

Final Analysis of GRIFFIN Supports Quadruplet Option in Multiple Myeloma

Single-Fraction Radiotherapy Plus PD-1 Inhibitor for Resistant Myeloma: Phase II Results

ASTRO 2023: Impact of Radiation Therapy in a New Era of Myeloma Management

What Drives Relapse After Targeted Immunotherapies for Myeloma?

ASTRO 2023: Tailoring Palliative Radiotherapy for Multiple Myeloma

2023 NCCN Hem: Revisiting Risk Stratification in Newly Diagnosed Myeloma

2023 NCCN Hem: Adding Immunotherapeutic Strategies to the Management Mix in Myeloma

Clinical Activity With Mezigdomide Plus Dexamethasone Reported in Resistant Myeloma

Standard Marrow Versus MRD Testing: Guiding Treatment Decisions in Myeloma

SOHO 2023: Final Overall Survival Trial Update on Combination Therapy in Myeloma

Study in France and Algeria: Unexpected Survival Similarities After ASCT in Myeloma

SOHO 2023: Personalized, Multidisciplinary Approach to Managing Myeloma in Frail Adults

Motixafortide Plus Filgrastim Approved by FDA for ASCT in Multiple Myeloma

Cryopreserved Autologous Peripheral Blood Hematopoietic Cells: Patterns in Use and Related Costs

Can Phenotypic Patterns in Multiple Myeloma Correlate With Clinical Outcomes?

Potential Immunogenic Cell Death–Related Predictor of Therapeutic Response in Myeloma

Researchers Focus on Affinity Tuning of CAR T Cells in Myeloma to Reduce Toxicity

Underrepresentation of Non-White Patients in Multiple Myeloma Clinical Trials

FDA Grants Accelerated Approval to Elranatamab-bcmm in Treatment of Relapsed or Refractory Myeloma

FDA Approves Talquetamab-tgvs for Treatment of Relapsed or Refractory Multiple Myeloma

Bortezomib-Induced Peripheral Neuropathy in Black Patients With Newly Diagnosed Myeloma

Use of Teclistamab in Patients With Myeloma Who Had Received Anti-BCMA Therapy

Real-World Analysis of Bridging Therapy Before CAR T-Cell Therapy for Resistant Myeloma

DREAMM-3 Trial: Belantamab Mafodotin Versus Pomalidomide Plus Dexamethasone in Relapsed Myeloma

Long-Terms Results With Isatuximab-Based Regimen for 1q21-Positive Patients With Myeloma

Final Analysis From CARTITUDE-1 Trial of Ciltacabtagene Autoleucel in Resistant Myeloma

Observations on Global Disparities in Toxicity From Myeloma Treatment

Does Bispecific Antibody Therapy for Relpased Multiple Myeloma Pose a Risk of Infection?

5-Year Follow-up of LEGEND-2 Trial of Immunotherapy for Resistant Myeloma

Can Clonal Diversity Complement MRD Assessment in Predicting Outcomes in Myeloma?

CARTITUDE-4 Shows Potential of Ciltacabtagene Autoleucel in Myeloma After First Relapse

Isatuximab With and Without Lenalidomide Under Study in High-Risk Smoldering Myeloma

Extended Follow-up From MagnetisMM-3 on Use of Elranatamab in Resistant Myeloma

Update From Phase II MonumenTAL-1 Study of Talquetamab in Resistant Myeloma

EHA 2023: Use of Idecabtagene Vicleucel in High-Risk Subgroups With Resistant Myeloma

ASCO 2023: New BCMA-Directed CAR T-Cell Therapy Under Study in Resistant Myeloma

EHA 2023: MRD as a Surveillance Tool in MASTER Trial of Quadruplet Therapy for Multiple Myeloma

ASCO 2023: Infection Profile and Immune Function With Talquetamab Monotherapy for Myeloma

EHA 2023: Research Explores T-Cell Exhaustion and CAR T-Cell Therapy for Myeloma

ASCO 2023: Maintenance Triplet Regimen for High-Risk Myeloma

EHA 2023: Therapeutic Implications of Distinct T-Cell Profile of Older Patients With Multiple Myeloma

ASCO 2023: New Data on Efficacy, Safety, Dosage of Bispecific Antibody Linvoseltamab

EHA 2023: Could the Oxidative Phosphorylation Pathway Be a Therapeutic Target in Multiple Myeloma?

ASCO 2023: CARTITUDE-4 Reports Benefit of Ciltacabtagene Autoleucel in Lenalidomide-Refractory Myeloma

ASCO 2023: Elotuzumab-Based Combination Regimen Under Study in First-Line Setting for Myeloma